WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance

Neoplasma

Volumn 56, Issue 5, 2009, Pages 393-397

  Otahalova, E ^a   Ullmannova Benson, V ^a,b   Klamova, H ^a   Haskovec, C ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

BCR ABL; CML; Drug resistance; Imatinib; WT1

Indexed keywords

BCR ABL PROTEIN; IMATINIB; KI 67 ANTIGEN; WT1 PROTEIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKOCYTE; CELL STRAIN K 562; DRUG RESISTANCE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; KI-67 ANTIGEN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; WT1 PROTEINS;

EID: 69849085499     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_05_393     Document Type: Article

References (21)

1. SHTIVELMAN E, LIFSHITZ B, GALE RP et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554. doi:10.1038/315550a0 PMid:2989692
2. LEE S, KIM YJ, MIN CK et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449-3457. doi:10.1182/blood-2004-09-3785 PMid:15657178 (Pubitemid 40628185)
3. KINDLER T, BREITENBUECHER F, MARX A et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003; 101: 2960-2962. doi:10.1182/blood-2002-05-1469 PMid:12480706
4. DRUKER BJ, TAMURA S, BUCHDUNGER E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561-566. doi:10.1038/nm0596-561 PMid:8616716 (Pubitemid 26151518)
5. HEINRICH MC, GRIFFITH DJ, DRUKER BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
6. DRUKER BJ et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med 2006; 355: 2408-2417. doi:10.1056/NEJMoa062867 PMid:17151364 (Pubitemid 44903745)
7. BRANFORD S, RUDZKI Z, WALSH S et al. Detection of BCRABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-1183 doi:10.1182/blood-2002-09-2896 PMid:12623848
8. BARNES DJ, PALAIOLOGOU D, PANOUSOPOULOU E et al. BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912-8919. doi:10.1158/0008-5472. CAN-05-0076 PMid:16204063
9. MAHON FX, BELLOC F, LAGARDE V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373. doi:10.1182/blood.V101.6.2368 PMid:12609962
10. THOMAS J, WANG L, CLARK RE et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745. doi:10.1182/blood-2003-12-4276 PMid:15315971
11. DONATO Nj, WU JY, STAPLEY J et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-677. doi:10.1158/0008-5472.CAN-03-1484 PMid:14744784 (Pubitemid 38120909)
12. CILLONI D, MESSA F, GOTTARDI E et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004; 101: 979-988. doi:10.1002/cncr.20457 PMid:15329907
13. CALL KM, GLASER T, ITO CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520. doi:10.1016/0092-8674(90)90601-A PMid:2154335 (Pubitemid 20060879)
14. FRAIZER GC, PATMASIRIWAT P, ZHANG X et al. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 1995; 86: 4704-4706.
15. NAKATSUKA S, OJI Y, HORIUCHI T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804-814.
16. HAŠKOVEC C, PONZETTO C, POLÁK J et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 1998; 103: 1104-1108. doi:10.1046/j.1365-2141.1998.01098.x PMid:9886327
17. GABERT J, BEILLARD E, VAN DER VELDEN VH et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357. doi:10.1038/sj.leu.2403135 PMid:14562125
18. JOSKE Dj. Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med J Aust 2008; 189: 277-282.
19. CILLONI D, SAGLIO G. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin Hematol 2003; 40: 37-41. (Pubitemid 36687158)
20. SCHOLZEN T, GERDES J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322. doi:10.1002/(SICI)1097-4652(200003)182: 3〈311::AID-JCP1〉3.0.CO;2-9 PMid:10653597
21. DRUKER BJ, TALPAZ M, RESTA DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. doi:10.1056/NEJM200104053441401 PMid:11287972 (Pubitemid 32267972)